

Date: 16th July, 2020
To, The Manager,
Listing Department,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai — 400 001
BSE Scrip Code: 540359

Subject: Update regarding production of intermediates of 'Hydroxy chloroquine'

Dear Sir /Madam,

In continuation of our corporate announcement dated 25th April, 2020 in which we have informed about the production of intermediates of 'Hydroxy chloroquine' ('Product') on the basis of process and specifications provided by the Cadila Healthcare Ltd (CHL). In this regard we hereby informing that due to acute decline in demand of product the **Company has temporarily stopped the production of 'Hydroxy chloroquine' till further order and instructions of CHL.**

Further Company is in business of manufacturing of Pharmaceutical Drug Intermediates, Bulk Drugs and Specialty chemicals hence production / stop production of intermediates of 'Hydroxy chloroquine' is general character, nature of our business and it is not material events as specified in Part B of Schedule III, read with Regulation 30(4) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. Company is voluntarily making this disclosure by following good corporate governance practice.

Thanking you,

Yours faithfully,

For Parmax Pharma Limited

Yash Vora
Yash Vora
Company Secretary

